Archives
-
Proteoform-Specific Drug Targeting in Native Membranes
2026-09-13
A 2025 Nature Chemistry study introduces native top-down mass spectrometry for resolving proteoform-specific interactions in intact membrane signaling systems. Using rhodopsin and retina rod disc membranes, the authors connect lipid modifications to receptor-complex assembly and reveal differential off-target binding by PDE5 inhibitors.
-
Netarsudil (AR-13324) Research Workflows
2026-09-12
Netarsudil (AR-13324) links ROCK pathway biology with practical trabecular meshwork assays and emerging siRNA nanoparticle codelivery. This guide covers formulation, cytoskeletal readouts, controls, and troubleshooting for ocular and fibrosis-focused research.
-
Multiplex PBMC Flow Cytometry for Immunomodulator Screening
2026-09-11
Brox and Hackstein developed a human PBMC-based multiplex flow cytometry assay that measures T-cell proliferation and activation alongside B-cell costimulatory responses. Its validation framework and pilot screen of 295 immunology-related compounds show how multiparametric phenotyping can improve immunomodulator screening beyond single-endpoint assays.
-
Palomid 529 (P529) for ESCC Resistance Studies
2026-09-11
Palomid 529 (P529) provides a practical way to interrogate dual mTORC1/mTORC2 signaling in esophageal squamous cell carcinoma models. This workflow connects RCN2-driven cisplatin resistance with tumor angiogenesis inhibition and radiotherapy enhancement while emphasizing assay controls, timing, and troubleshooting.
-
Antiseptics for Burns: Evidence from a Cochrane Review
2026-09-10
The 2017 Cochrane review examined whether topical antiseptics improve healing, infection outcomes, pain, or safety in burn wounds compared with alternative treatments. Its main contribution was a structured comparison of heterogeneous clinical evidence, showing that uncertainty and study limitations prevent firm conclusions about the superiority of most antiseptic strategies.
-
Tivozanib (AV-951) Assay Workflow Guide
2026-09-10
Build more informative VEGFR inhibition experiments with Tivozanib (AV-951), from formulation and dose design to orthogonal measurements of growth arrest and cell death. This workflow separates assay sensitivity from true cytotoxicity, supporting better decisions in renal cell carcinoma and anti-angiogenic research.
-
Tivozanib (AV-951): Selective VEGFR Inhibition
2026-09-09
Tivozanib, also called AV-951, is a selective VEGFR tyrosine kinase inhibitor used in renal cell carcinoma research. Its reported 160 pM VEGFR-2 IC50, defined assay scope, and distinct viability-response considerations support careful use in anti-angiogenic experiments.
-
Ranolazine: A Translational Map from Heart to Liver
2026-09-09
Ranolazine offers a mechanistically distinct platform for connecting late sodium current control with myocardial relaxation, glucose oxidation enhancement, and hepatic metabolic research. This thought-leadership guide translates those mechanisms into rigorous cardiac and liver workflows while defining the limits of emerging cross-domain hypotheses.
-
Itraconazole and the Autophagy Axis in Candida Biofilms
2026-09-08
A translational framework for using Itraconazole to investigate Candida biofilm resistance, PP2A-regulated autophagy, CYP3A4-mediated interactions, and the path from mechanistic assays to animal models.
-
Berbamine hydrochloride in Ferroptosis Research
2026-09-08
Berbamine hydrochloride is a versatile research probe for connecting STAT3, calcium-homeostasis, NF-κB, and cell-death readouts in cancer models. This workflow shows how to use its reported cytotoxicity as a starting point while testing, rather than assuming, links to ferroptosis and the METTL16-SENP3-LTF axis in hepatocellular carcinoma.
-
Ruxolitinib phosphate: JAK1/2 Workflow Guide
2026-09-07
Ruxolitinib phosphate enables controlled JAK1/JAK2 inhibition for cytokine signaling studies, autoimmune disease models, and mechanistic cancer assays. This guide translates its selectivity and recent anaplastic thyroid cancer findings into practical preparation, experimental, and troubleshooting workflows.
-
SGC-CBP30 in Super-Enhancer LUAD Research
2026-09-07
SGC-CBP30 provides a selective way to test whether CREBBP/EP300 bromodomain activity supports super-enhancer-driven transcription in lung adenocarcinoma models. This practical guide connects the compound to TGF-β/SMAD3 biology, reporter assays, chromatin workflows, FRAP, and troubleshooting strategies.
-
Patient-Derived Gastric Cancer Assembloids Explained
2026-09-05
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. The model reveals how tumor–stroma composition changes transcriptional states and drug sensitivity, offering a more physiologically relevant platform for resistance studies and personalized treatment testing.
-
Hagenia abyssinica Field Trials Against Biomphalaria
2026-09-04
This study advances Hagenia abyssinica as a plant-based molluscicide by testing flower fractions against Biomphalaria snails in a small-scale field setting and evaluating acute toxicity in Nile tilapia. Its key practical finding is that fish were more sensitive than snails to the 70% ethanol extract, highlighting the need to integrate nontarget-organism testing into schistosomiasis control research.
-
Pexmetinib (ARRY-614): Reading Kinase Data
2026-09-04
Pexmetinib (ARRY-614) is a dual p38 MAPK and Tie2 inhibitor for studying cytokine regulation, inflammation, and hematologic disease biology. This guide explains how recent p38α dephosphorylation research changes assay interpretation and improves target-attribution strategies.